These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19498341)

  • 1. Racial differences in blood pressure response to calcium channel blocker monotherapy: a meta-analysis.
    Nguyen TT; Kaufman JS; Whitsel EA; Cooper RS
    Am J Hypertens; 2009 Aug; 22(8):911-7. PubMed ID: 19498341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overlap between whites and blacks in response to antihypertensive drugs.
    Sehgal AR
    Hypertension; 2004 Mar; 43(3):566-72. PubMed ID: 14757779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of hypertension in African Americans.
    Ferdinand KC; Armani AM
    Crit Pathw Cardiol; 2007 Jun; 6(2):67-71. PubMed ID: 17667868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
    Wright JT; Dunn JK; Cutler JA; Davis BR; Cushman WC; Ford CE; Haywood LJ; Leenen FH; Margolis KL; Papademetriou V; Probstfield JL; Whelton PK; Habib GB;
    JAMA; 2005 Apr; 293(13):1595-608. PubMed ID: 15811979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks.
    Hall WD; Reed JW; Flack JM; Yunis C; Preisser J
    Arch Intern Med; 1998 Oct; 158(18):2029-34. PubMed ID: 9778203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nocturnal blood pressure in treated hypertensive African Americans Compared to treated hypertensive European Americans.
    Hebert LA; Agarwal G; Ladson-Wofford SE; Reif M; Hiremath L; Carlton SG; Nahman NS; Falkenhain ME; Agarwal A
    J Am Soc Nephrol; 1996 Oct; 7(10):2130-4. PubMed ID: 8915972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microalbuminuria, macroalbuminuria and uncontrolled blood pressure among diagnosed hypertensive patients: the aspect of racial disparity in the NHANES study.
    Liu X; Wang K; Wang L; Tsilimingras D
    Hypertens Res; 2013 Dec; 36(12):1100-6. PubMed ID: 23945963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Margolis KL; Piller LB; Ford CE; Henriquez MA; Cushman WC; Einhorn PT; Colon PJ; Vidt DG; Christian R; Wong ND; Wright JT; Goff DC;
    Hypertension; 2007 Nov; 50(5):854-61. PubMed ID: 17846352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
    Everett BM; Glynn RJ; Danielson E; Ridker PM;
    Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Evid Based Child Health; 2014 Sep; 9(3):498-580. PubMed ID: 25236305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Race/Ethnicity-Specific Changes in Antihypertensive Medication Classes Initiated Among Medicare Beneficiaries With the Eighth Joint National Committee Panel Member Report.
    Colvin CL; King JB; Oparil S; Wright JT; Ogedegbe G; Mohanty A; Hardy ST; Huang L; Hess R; Muntner P; Bress A
    JAMA Netw Open; 2020 Nov; 3(11):e2025127. PubMed ID: 33206191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cochrane in context: pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS
    Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Racial Differences in Blood Pressure Control from Users of Antihypertensive Monotherapy: Results from the ELSA-Brasil Study.
    Sousa CT; Ribeiro A; Barreto SM; Giatti L; Brant L; Lotufo P; Chor D; Lopes AA; Mengue SS; Baldoni AO; Figueiredo RC
    Arq Bras Cardiol; 2022 Mar; 118(3):614-622. PubMed ID: 35319612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
    Miranda RD; Mion D; Rocha JC; Kohlmann O; Gomes MA; Saraiva JF; Amodeo C; Filho BL
    Clin Ther; 2008 Sep; 30(9):1618-28. PubMed ID: 18840367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K; Ogihara T; Saruta T; Kuramoto K;
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives.
    Weir MR; Chrysant SG; McCarron DA; Canossa-Terris M; Cohen JD; Gunter PA; Lewin AJ; Mennella RF; Kirkegaard LW; Hamilton JH; Weinberger MH; Weder AB
    Hypertension; 1998 May; 31(5):1088-96. PubMed ID: 9576119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological interventions for hypertension in children.
    Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh R
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD008117. PubMed ID: 24488616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
    Mugendi GA; Mutua FM; Natale P; Esterhuizen TM; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011064. PubMed ID: 33000470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.